Pharma Mar, S.A.

BME:PHM Stock Report

Market Cap: €1.3b

Pharma Mar Management

Management criteria checks 2/4

Pharma Mar's CEO is Jose Fernandez Sousa-Faro, appointed in Jan 1986, has a tenure of 39.92 years. directly owns 6.48% of the company’s shares, worth €85.62M. The average tenure of the management team and the board of directors is 14.8 years and 3.5 years respectively.

Key information

Jose Fernandez Sousa-Faro

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure39.9yrs
CEO ownership6.5%
Management average tenure14.8yrs
Board average tenure3.5yrs

Recent management updates

Recent updates

There May Be Underlying Issues With The Quality Of Pharma Mar's (BME:PHM) Earnings

Nov 07
There May Be Underlying Issues With The Quality Of Pharma Mar's (BME:PHM) Earnings

Pharma Mar, S.A. (BME:PHM) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Nov 02
Pharma Mar, S.A. (BME:PHM) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Is Pharma Mar (BME:PHM) A Risky Investment?

Oct 29
Is Pharma Mar (BME:PHM) A Risky Investment?

Risks To Shareholder Returns Are Elevated At These Prices For Pharma Mar, S.A. (BME:PHM)

Aug 03
Risks To Shareholder Returns Are Elevated At These Prices For Pharma Mar, S.A. (BME:PHM)

Pharma Mar (BME:PHM) Will Pay A Larger Dividend Than Last Year At €0.80

Jun 16
Pharma Mar (BME:PHM) Will Pay A Larger Dividend Than Last Year At €0.80

Pharma Mar (BME:PHM) Has Announced That It Will Be Increasing Its Dividend To €0.80

May 23
Pharma Mar (BME:PHM) Has Announced That It Will Be Increasing Its Dividend To €0.80
User avatar

ZEPZELCA's EMA Submission Will Broaden Cancer Treatment Availability In Europe

Successful approval of ZEPZELCA in Europe and new markets could significantly boost PharmaMar’s future revenues, leveraging positive trial results.

We Think Shareholders Should Be Aware Of Some Factors Beyond Pharma Mar's (BME:PHM) Profit

Mar 06
We Think Shareholders Should Be Aware Of Some Factors Beyond Pharma Mar's (BME:PHM) Profit

There's Reason For Concern Over Pharma Mar, S.A.'s (BME:PHM) Massive 27% Price Jump

Feb 13
There's Reason For Concern Over Pharma Mar, S.A.'s (BME:PHM) Massive 27% Price Jump

Pharma Mar, S.A.'s (BME:PHM) Price Is Right But Growth Is Lacking After Shares Rocket 55%

Oct 16
Pharma Mar, S.A.'s (BME:PHM) Price Is Right But Growth Is Lacking After Shares Rocket 55%

Pharma Mar, S.A.'s (BME:PHM) Share Price Boosted 27% But Its Business Prospects Need A Lift Too

Jul 28
Pharma Mar, S.A.'s (BME:PHM) Share Price Boosted 27% But Its Business Prospects Need A Lift Too

Pharma Mar (BME:PHM) Will Pay A Larger Dividend Than Last Year At €0.65

Jun 01
Pharma Mar (BME:PHM) Will Pay A Larger Dividend Than Last Year At €0.65

Pharma Mar, S.A.'s (BME:PHM) Shares Bounce 29% But Its Business Still Trails The Industry

May 28
Pharma Mar, S.A.'s (BME:PHM) Shares Bounce 29% But Its Business Still Trails The Industry

Pharma Mar, S.A. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Mar 03
Pharma Mar, S.A. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Here's Why Pharma Mar (BME:PHM) Has A Meaningful Debt Burden

Jan 25
Here's Why Pharma Mar (BME:PHM) Has A Meaningful Debt Burden

Pharma Mar, S.A. (BME:PHM) Shares Could Be 30% Below Their Intrinsic Value Estimate

Apr 28
Pharma Mar, S.A. (BME:PHM) Shares Could Be 30% Below Their Intrinsic Value Estimate

We Believe That Pharma Mar's (BME:PHM) Weak Earnings Are A Good Indicator Of Underlying Profitability

Mar 08
We Believe That Pharma Mar's (BME:PHM) Weak Earnings Are A Good Indicator Of Underlying Profitability

Analyst Forecasts Just Became More Bearish On Pharma Mar, S.A. (BME:PHM)

Mar 05
Analyst Forecasts Just Became More Bearish On Pharma Mar, S.A. (BME:PHM)

Pharma Mar (BME:PHM) Has A Rock Solid Balance Sheet

Feb 09
Pharma Mar (BME:PHM) Has A Rock Solid Balance Sheet

We Think Pharma Mar (BME:PHM) Can Manage Its Debt With Ease

Oct 27
We Think Pharma Mar (BME:PHM) Can Manage Its Debt With Ease

An Intrinsic Calculation For Pharma Mar, S.A. (BME:PHM) Suggests It's 21% Undervalued

Sep 27
An Intrinsic Calculation For Pharma Mar, S.A. (BME:PHM) Suggests It's 21% Undervalued

Does Pharma Mar (BME:PHM) Have A Healthy Balance Sheet?

Jul 15
Does Pharma Mar (BME:PHM) Have A Healthy Balance Sheet?

Growth Investors: Industry Analysts Just Upgraded Their Pharma Mar, S.A. (BME:PHM) Revenue Forecasts By 24%

May 04
Growth Investors: Industry Analysts Just Upgraded Their Pharma Mar, S.A. (BME:PHM) Revenue Forecasts By 24%

Pharma Mar (BME:PHM) Has A Pretty Healthy Balance Sheet

Apr 11
Pharma Mar (BME:PHM) Has A Pretty Healthy Balance Sheet

There Is A Reason Pharma Mar, S.A.'s (BME:PHM) Price Is Undemanding

Mar 16
There Is A Reason Pharma Mar, S.A.'s (BME:PHM) Price Is Undemanding

CEO

Jose Fernandez Sousa-Faro

39.9yrs
Tenure
€294,000
Compensation

Mr. José María Fernández Sousa-Faro, Ph D., founded Pharma Mar, S.A.U. in 1986. He Founded Noscira, S.A., in 2000.He serves as the Chief Executive Officer and President of Pharma Mar, S.A.U. He serves as...

Leadership Team

NamePositionTenureCompensationOwnership
Jose Fernandez Sousa-Faro
Founder39.9yrs€294.00k6.48%
€ 84.4m
Pedro Fernandez Puentes
Executive Vice-Chairmanno data€124.00k0.00058%
€ 7.6k
Juan Carretero
Founderno datano datano data
María de Francia Caballero
Chief Financial Officer25.9yrsno datano data
José Moreno Martinez-Losa
Head of Capital Markets & Investor Relations10.9yrsno datano data
Juan Pulido
General Counsel & Secretary of the Board of Directors6.3yrsno datano data
Sandra Sanchez
Global Compliance Head5.6yrsno datano data
Lara Vadillo
Communication Directorno datano datano data
Belén Veramendi
Director of Corporate Development3.9yrsno datano data
Luis Cuenca
Director of Human Resources & IT22.4yrsno datano data
Luis Mora Capitan
Managing Director of Oncology & Virology Business Units18.7yrsno datano data
Pascal Besman
Senior Vice President of Strategic Developmentno datano datano data
14.8yrs
Average Tenure

Experienced Management: PHM's management team is seasoned and experienced (14.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Jose Fernandez Sousa-Faro
Founderno data€294.00k6.48%
€ 84.4m
Pedro Fernandez Puentes
Executive Vice-Chairmanno data€124.00k0.00058%
€ 7.6k
Eduardo Serra Rexach
Independent Other External Director4.9yrs€35.00kno data
M. Solchaga Catalan
Independent Other External Directorno data€35.00kno data
Montserrat Andrade Detrell
Proprietary Directorno data€34.00k5.56%
€ 72.4m
Blanca Hernandez Rodriguez
Independent Director6.9yrsno datano data
Maria Sandra Mera
Representative Proprietary Director5yrsno datano data
Rosa Maria Alonso
Independent Director3.5yrsno datano data
Mariano Rodriguez
Independent Coordinating Director3.5yrsno datano data
Emiliano Aller
Independent Director3.5yrsno datano data
Fernando Santos
Independent Other External Directorno datano datano data
Soledad Miranda
Independent Director2.6yrsno datano data
3.5yrs
Average Tenure

Experienced Board: PHM's board of directors are considered experienced (3.5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/12/24 19:37
End of Day Share Price 2025/12/24 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Pharma Mar, S.A. is covered by 12 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Guilherme SampaioBanco BPI, S.A.
Patricia CifuentesBestinver Sociedad De Valores, S.A
Keay NakaeChardan Capital Markets, LLC